Tag Archives: Stephen J. Schuster MD

Novartis: Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development

Posted on 4, May 2018 by

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , , , , ,